...
首页> 外文期刊>Journal of hypertension >Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat.
【24h】

Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat.

机译:钙敏感受体调节大鼠体内和体外的肾素释放。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: Calcium-sensing receptors (CaSRs) have been localized in the juxtaglomerular apparatus where they may contribute to the regulation of renin release. In the present study, we investigated the in-vitro and in-vivo effects of the calcimimetic R-568 on renin release. METHODS: In vitro, the effect of calcimimetics on renin release was assessed by incubating freshly isolated rat juxtaglomerular cells with or without R-568 (1 and 10 mumol/l) in serum-free medium in the presence or absence of forskolin or CaCl2. In vivo, we measured the impact of R-568 (20 ng/min intravenously) on the acute changes in plasma renin activity (PRA) induced by either a 90 min infusion of the angiotensin-converting enzyme inhibitor captopril, or the beta-receptor agonist isoproterenol, or of a vehicle in or after a furosemide challenge in conscious Wistar rats. RESULTS: In vitro, R-568 dose-dependently blunted renin release, but also reduced the increase in renin due to forskolin (P < 0.01). Both isoproterenol and enalapril increased in vivo PRA to 3.1 +/- 0.3 and 3.7 +/- 0.5 ng Ang I/ml per h, respectively (P < 0.01), compared with vehicle (1.5 +/- 0.2 ng Ang I/ml per h). R-568 significantly reduced PRA to 2.1 +/- 0.1 ng/ml per h in isoproterenol-treated rats and to 1.6 +/- 0.2 ng/ml per h in enalapril-treated rats (P < 0.05). In low-salt treated animals, acute infusion of furosemide increased PRA from 8.7 +/- 3.2 to 18.6 +/- 2.3, whereas R-568 partially blunted this rise to 11.2 +/- 1.5 (P = 0.02). In vivo, R-568 significantly lowered serum calcium and PTH1-84, but the drug-induced changes in PRA were independent of the changes in calcium and parathyroid hormone. CONCLUSION: After the recent discovery of CaSRs in juxtaglomerular cells of mice, our results confirm the presence of such receptors in rats and demonstrate that these receptors modulate renin release both in vitro and in vivo. This suggests that CaSRs play a role as a regulatory pathway of renin release.
机译:目的:钙敏感受体(CaSRs)已经定位在肾小球旁,可能有助于调节肾素的释放。在本研究中,我们研究了拟钙剂R-568对肾素释放的体外和体内作用。方法:在存在或不存在毛喉素或CaCl2的情况下,在无血清培养基中孵育新鲜分离的大鼠近肾小球细胞(含或不含R-568(1和10μmol/ l))来评估拟钙剂对肾素释放的影响。在体内,我们测量了R-568(静脉注射20 ng / min)对输注90分钟的血管紧张素转化酶抑制剂卡托普利或β受体诱导的血浆肾素活性(PRA)急性变化的影响。激动剂异丙肾上腺素,或在有意识的Wistar大鼠中接受呋塞米治疗后的载体。结果:在体外,R-568剂量依赖性地抑制了肾素的释放,但也减少了由于毛喉素引起的肾素的增加(P <0.01)。相比于赋形剂(1.5 +/- 0.2 ng Ang I / ml / h),异丙肾上腺素和依那普利的体内PRA分别提高至每小时3.1 +/- 0.3 ng Ang I / ml(3.7 <0.5 ng Ang I / ml)(P <0.01)。 H)。在异丙肾上腺素治疗的大鼠中,R-568的PRA显着降低至每小时2.1 +/- 0.1 ng / ml,在依那普利治疗的大鼠中,PRA降至每小时1.6 +/- 0.2 ng / ml(P <0.05)。在低盐治疗的动物中,急性输注速尿使PRA从8.7 +/- 3.2增至18.6 +/- 2.3,而R-568部分减弱了其上升至11.2 +/- 1.5(P = 0.02)。在体内,R-568显着降低了血清钙和PTH1-84,但是药物引起的PRA的变化与钙和甲状旁腺激素的变化无关。结论:最近在小鼠的肾小球细胞中发现了CaSRs之后,我们的结果证实了大鼠体内这种受体的存在,并证明这些受体在体内和体外均可调节肾素的释放。这表明CaSRs是肾素释放的调节途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号